Attitudes of potential recipients toward emerging visual prosthesis technologies.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
06 07 2023
06 07 2023
Historique:
received:
21
01
2023
accepted:
12
06
2023
medline:
10
7
2023
pubmed:
7
7
2023
entrez:
6
7
2023
Statut:
epublish
Résumé
With the advent of multiple visual prosthesis devices to treat blindness, the question of how potential patients view such interventions becomes important in order to understand the levels of expectation and acceptance, and the perceived risk-reward balance across the different device approaches. Building on previous work on single device approaches done with blind individuals in Chicago and Detroit, USA, Melbourne, Australia, and Bejing, China, we investigated attitudes in blind individuals in Athens, Greece with coverage expanded to three of the contemporary approaches, Retinal, Thalamic, and Cortical. We presented an informational lecture on the approaches, had potential participants fill out a preliminary Questionnaire 1, then organized selected subjects into focus groups for guided discussion on visual prostheses, and finally had these subjects fill out a more detailed Questionnaire 2. We report here the first quantitative data that compares multiple prosthesis approaches. Our primary findings are that for these potential patients, perceived risk continues to outweigh perceived benefits, with the Retinal approach having the least negative overall impression and the Cortical approach the most negative. Concerns about the quality of restored vision were primary. Factors that drove the choice of hypothetical participation in a clinical trial were age and years of blindness. Secondary factors focused on positive clinical outcomes. The focus groups served to swing the impressions of each approach from neutrality toward the extremes of a Likert scale, and shifted the overall willingness to participate in a clinical trial from neutral to negative. These results, coupled with informal assessment of audience questions after the informational lecture, suggest that a substantial improvement in performance over currently available devices will be necessary before visual prostheses gain wide acceptance.
Identifiants
pubmed: 37414798
doi: 10.1038/s41598-023-36913-8
pii: 10.1038/s41598-023-36913-8
pmc: PMC10325978
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
10963Informations de copyright
© 2023. The Author(s).
Références
Sci Rep. 2016 Nov 22;6:36329
pubmed: 27874058
Transl Vis Sci Technol. 2021 Aug 12;10(10):12
pubmed: 34581770
J Neural Eng. 2023 Feb 15;20(1):
pubmed: 36634357
Arch Ophthalmol. 2007 Apr;125(4):544-50
pubmed: 17420375
Sci Rep. 2022 Jul 28;12(1):12953
pubmed: 35902596
IEEE Trans Biomed Eng. 2009 Jan;56(1):172-8
pubmed: 19224730
Clin Exp Optom. 2017 Mar;100(2):144-150
pubmed: 27558213
Invest Ophthalmol Vis Sci. 2010 Apr;51(4):1801-5
pubmed: 20071669
Eye (Lond). 2012 Apr;26(4):501-9
pubmed: 22422033
Brain Stimul. 2022 Sep-Oct;15(5):1163-1177
pubmed: 35985472
Sci Rep. 2021 May 27;11(1):11121
pubmed: 34045485
Brain Res. 2015 Jan 21;1595:51-73
pubmed: 25446438
J Neural Eng. 2009 Jun;6(3):035003
pubmed: 19458402
Annu Rev Biomed Eng. 2008;10:339-68
pubmed: 18429703
Proc Natl Acad Sci U S A. 2007 May 1;104(18):7670-5
pubmed: 17452646
Science. 2020 Dec 4;370(6521):1191-1196
pubmed: 33273097
PLoS Negl Trop Dis. 2013;7(2):e2084
pubmed: 23469307
Scand J Occup Ther. 2014 Jul;21(4):267-76
pubmed: 24784723
J Clin Invest. 2021 Dec 1;131(23):
pubmed: 34665780
J Neural Eng. 2014 Apr;11(2):020301
pubmed: 24556526
Trends Biotechnol. 2013 Oct;31(10):562-71
pubmed: 23953722
Nature. 2018 May;557(7705):359-367
pubmed: 29769667
Ophthalmologica. 1999;213(1):48-53
pubmed: 9838257
J Neural Eng. 2018 Apr;15(2):021005
pubmed: 29350199
PLoS One. 2013 Sep 27;8(9):e73592
pubmed: 24086286
Contemp Clin Trials. 2012 Jul;33(4):628-32
pubmed: 22465307
Brain Res. 2016 Jan 1;1630:208-24
pubmed: 26348986
J Physiol. 1968 May;196(2):479-93
pubmed: 4871047
Cell. 2020 May 14;181(4):774-783.e5
pubmed: 32413298
JAMA Netw Open. 2020 Apr 1;3(4):e203560
pubmed: 32324240
Prog Retin Eye Res. 2016 Jan;50:89-107
pubmed: 26404104
Front Hum Neurosci. 2014 Nov 04;8:816
pubmed: 25408641
Sci Eng Ethics. 2013 Sep;19(3):1099-106
pubmed: 22729653
Acta Ophthalmol. 2015 Nov;93(7):642-50
pubmed: 26109392
J Am Geriatr Soc. 2014 Aug;62(8):1540-5
pubmed: 25040870
Disabil Rehabil Assist Technol. 2011;6(2):139-47
pubmed: 20815691
Bioelectron Med. 2018 Aug 13;4:12
pubmed: 32232088
J Neural Eng. 2016 Apr;13(2):025003
pubmed: 26905379
BMC Public Health. 2014 Aug 08;14:815
pubmed: 25103270
Front Neurosci. 2020 Feb 18;14:36
pubmed: 32132890
Br J Ophthalmol. 2006 Mar;90(3):272-5
pubmed: 16488942
Sci Rep. 2018 Nov 5;8(1):16310
pubmed: 30397211
Prog Retin Eye Res. 2013 Sep;36:1-23
pubmed: 23500412
Neurosurg Focus. 2009 Jul;27(1):E6
pubmed: 19569894
Invest Ophthalmol Vis Sci. 1999 Jan;40(1):12-9
pubmed: 9888421
Ophthalmology. 2018 Mar;125(3):432-443
pubmed: 29110946
Int Psychogeriatr. 2019 Jan;31(1):139-145
pubmed: 29798742
Ophthalmology. 2007 Feb;114(2):283-8
pubmed: 17270678
PLoS One. 2021 Feb 10;16(2):e0229189
pubmed: 33566851
Disabil Rehabil Assist Technol. 2016;11(4):301-9
pubmed: 25425410
Disabil Rehabil Assist Technol. 2012 Jul;7(4):304-13
pubmed: 22458249
Ophthalmology. 2020 Aug;127(8):1097-1104
pubmed: 32249038
Mil Med Res. 2019 Jun 5;6(1):19
pubmed: 31167653
JAMA Ophthalmol. 2018 Sep 1;136(9):989-995
pubmed: 29955805
J Neural Eng. 2007 Mar;4(1):S130-5
pubmed: 17325411
BMJ Open. 2013 Nov 07;3(11):e003471
pubmed: 24202057
Proc Biol Sci. 2013 Feb 20;280(1757):20130077
pubmed: 23427175
J Neural Eng. 2021 Mar 16;18(3):
pubmed: 33592588